Plasmin
- Generic Name
- Plasmin
- Brand Names
- Ryplazim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9001-91-6
- Unique Ingredient Identifier
- 1EF190B6M7
- Background
Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury.
In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh) for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with this rare congenital disease.
- Indication
Plasma-derived human plasminogen, marketed under the brand name Ryplazim, is indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
- Associated Conditions
- Type I Plasminogen Deficiency
- Associated Therapies
- -
Kedrion's Facility In Bolognana Approved By FDA To Produce RYPLAZIM
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.